Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells
Figure 2
Adoptively transferred HA-specific CD4+Thy1.1+ T cells demonstrate early activation and following depletion in cervical lymph nodes of A20HA brain tumor-bearing mice. ((a), (b), (c)) Flow cytometry of CD4+Thy1.1+CD44+ T cells from cervical lymph nodes on days 2, 9, and 16 after adoptive transfer. HA-specific CD4+Thy1.1+ T cells were injected i.v. into A20HA brain tumor-bearing mice 5 days after i.c. tumor inoculation (A20HA + T cells; left column) and tumor-free control mice (T cells; middle column). Naive mice represented a negative control (Neither; right column). Each group included three mice. Cervical lymph nodes were analyzed individually from each mouse by three-color FACS assay. A representative experiment among three equivalents is shown. (a) Dot plots show gated HA-specific CD4+Thy1.1+ T cells (upper right quadrants; numbers in the quadrants indicate percent cells in each). Bars show (b) percent of HA-specific CD4+Thy-1.1+ T cells and (c) intensity of CD44 expression in the gated population of CD4+Thy-1.1+ T cells. Data are represented as the mean ± SD, . .
